BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21354932)

  • 1. [Value of serum estradiol concentration in predicting the clinical outcome of IVF-ET in patients receiving long protocol of GnRHa].
    Ni H; Chen LN; Quan S; Li H; Hua R; Gao RH; Chen SM; Luo C
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Feb; 31(2):365-8. PubMed ID: 21354932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol.
    Lai TH; Lee FK; Lin TK; Horng SG; Chen SC; Chen YH; Wang PC
    Fertil Steril; 2009 Aug; 92(2):508-14. PubMed ID: 18701101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles.
    Wu Z; Li R; Ma Y; Deng B; Zhang X; Meng Y; Chen X; Liu P; Qiao J
    Reprod Biomed Online; 2012 May; 24(5):511-20. PubMed ID: 22417667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist.
    Var T; Tonguc E; Dogan M; Mollamahmutoglu L
    Gynecol Endocrinol; 2011 Aug; 27(8):558-61. PubMed ID: 20642381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist?
    Kyrou D; Popovic-Todorovic B; Fatemi HM; Bourgain C; Haentjens P; Van Landuyt L; Devroey P
    Hum Reprod; 2009 Nov; 24(11):2902-9. PubMed ID: 19671625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of pelvic inflammatory disease grades on in vitro fertilization-embryo transfer outcome].
    Yang XE; Zhang SY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):666-9. PubMed ID: 18241540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
    Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles.
    Kiliçdag EB; Haydardedeoglu B; Cok T; Hacivelioglu SO; Bagis T
    Arch Gynecol Obstet; 2010 Apr; 281(4):747-52. PubMed ID: 19862542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH).
    Chen QJ; Sun XX; Li L; Gao XH; Wu Y; Gemzell-Danielsson K; Cheng LN
    Acta Obstet Gynecol Scand; 2007; 86(7):849-54. PubMed ID: 17611831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate.
    Yang JH; Chen HF; Lien YR; Chen SU; Ho HN; Yang YS
    J Reprod Med; 2001 May; 46(5):434-8. PubMed ID: 11396368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
    Serna J; Cholquevilque JL; Cela V; Martínez-Salazar J; Requena A; Garcia-Velasco JA
    Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.